Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

HRTX - Heron Therapeutics Inc


IEX Last Trade
1.92
-0.010   -0.521%

Share volume: 1,423,635
Last Updated: Fri 30 Aug 2024 09:59:58 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$1.93
-0.01
-0.52%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
24%
Profitability 25%
Dept financing 7%
Liquidity 66%
Performance 16%
Company vs Stock growth
vs
Performance
5 Days
-1.03%
1 Month
-31.32%
3 Months
-44.06%
6 Months
-28.52%
1 Year
14.20%
2 Year
-50.77%
Key data
Stock price
$1.92
P/E Ratio 
0.00
DAY RANGE
N/A - N/A
EPS 
$0.00
52 WEEK RANGE
$0.50 - $3.93
52 WEEK CHANGE
$0.23
MARKET CAP 
292.719 M
YIELD 
N/A
SHARES OUTSTANDING 
151.668 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/11/2024
BETA 
2.03
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,218,554
AVERAGE 30 VOLUME 
$2,540,152
Company detail
CEO: Barry Quart
Region: US
Website: http://www.herontx.com/
Employees: 283
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

heron therapeutics, inc. (formerly a.p. pharma, inc.) is a specialty pharmaceutical company developing products using its proprietary biochronomer™ polymer-based drug delivery platform. this drug delivery platform is designed to improve the therapeutic profile of injectable pharmaceuticals by converting them from products that must be injected once or twice per day to products that need to be injected only once every one or two weeks.

Recent news